Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Optimized Scintillator YAG:Pr Nanoparticles for X-ray Inducible Photodynamic Therapy.

Sapre AA, Novitskaya E, Vakharia V, Cota A, Wrasidlo W, Hanrahan SM, Derenzo S, Makale MT, Graeve OA.

Mater Lett. 2018 Oct 1;228:49-52. doi: 10.1016/j.matlet.2018.05.090. Epub 2018 May 20.

PMID:
30505045
2.

The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.

Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, Bonhaus D.

Sci Rep. 2018 Nov 1;8(1):16165. doi: 10.1038/s41598-018-34490-9.

3.

α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.

Prots I, Grosch J, Brazdis RM, Simmnacher K, Veber V, Havlicek S, Hannappel C, Krach F, Krumbiegel M, Schütz O, Reis A, Wrasidlo W, Galasko DR, Groemer TW, Masliah E, Schlötzer-Schrehardt U, Xiang W, Winkler J, Winner B.

Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7813-7818. doi: 10.1073/pnas.1713129115. Epub 2018 Jul 10.

4.

Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease.

Kouroupi G, Taoufik E, Vlachos IS, Tsioras K, Antoniou N, Papastefanaki F, Chroni-Tzartou D, Wrasidlo W, Bohl D, Stellas D, Politis PK, Vekrellis K, Papadimitriou D, Stefanis L, Bregestovski P, Hatzigeorgiou AG, Masliah E, Matsas R.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):E3679-E3688. doi: 10.1073/pnas.1617259114. Epub 2017 Apr 17.

5.

The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Fields JA, Metcalf J, Overk C, Adame A, Spencer B, Wrasidlo W, Florio J, Rockenstein E, He JJ, Masliah E.

J Neurovirol. 2017 Apr;23(2):290-303. doi: 10.1007/s13365-016-0502-z. Epub 2017 Jan 19.

6.

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik ÅA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, Trejo-Morales M, Overk CR, Winter S, Zhu C, Chesselet MF, Meier D, Moessler H, Konrat R, Masliah E.

Brain. 2016 Dec;139(Pt 12):3217-3236. Epub 2016 Sep 27.

7.

Small molecule NPT-440-1 inhibits ionic flux through Aβ1-42 pores: Implications for Alzheimer's disease therapeutics.

Gillman AL, Lee J, Ramachandran S, Capone R, Gonzalez T, Wrasidlo W, Masliah E, Lal R.

Nanomedicine. 2016 Nov;12(8):2331-2340. doi: 10.1016/j.nano.2016.06.001. Epub 2016 Jun 19.

8.

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease.

Kim C, Ojo-Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, Wrasidlo W, Adame A, Nchekwube E, Oyemade O, Okogun J, Chan M, Cottam H, Masliah E.

J Neuroinflammation. 2015 Dec 18;12:236. doi: 10.1186/s12974-015-0455-9.

9.

Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma.

Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao Y, Babic I, Nurmemmedov E, Pastorino S, Jiang P, Calligaris D, Agar N, Scadeng M, Pingle SC, Wrasidlo W, Makale MT, Kesari S.

Oncotarget. 2017 Apr 4;8(14):22370-22384. doi: 10.18632/oncotarget.5633.

10.

Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions.

Tsigelny IF, Sharikov Y, Kouznetsova VL, Greenberg JP, Wrasidlo W, Overk C, Gonzalez T, Trejo M, Spencer B, Kosberg K, Masliah E.

ACS Chem Neurosci. 2015 Mar 18;6(3):403-16. doi: 10.1021/cn500332w. Epub 2015 Jan 21.

11.

Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease.

Eleuteri S, Di Giovanni S, Rockenstein E, Mante M, Adame A, Trejo M, Wrasidlo W, Wu F, Fraering PC, Masliah E, Lashuel HA.

Neurobiol Dis. 2015 Feb;74:144-57. doi: 10.1016/j.nbd.2014.08.017. Epub 2014 Aug 28.

12.

Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, Paulino A, Gonzales T, Overk CR, Patrick C, Rockenstein E, Masliah E.

Br J Pharmacol. 2014 Dec;171(24):5757-73. doi: 10.1111/bph.12875.

13.

Structural diversity of Alzheimer's disease amyloid-β dimers and their role in oligomerization and fibril formation.

Tsigelny IF, Sharikov Y, Kouznetsova VL, Greenberg JP, Wrasidlo W, Gonzalez T, Desplats P, Michael SE, Trejo-Morales M, Overk CR, Masliah E.

J Alzheimers Dis. 2014;39(3):583-600. doi: 10.3233/JAD-131589.

14.

High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile.

Mukthavaram R, Jiang P, Saklecha R, Simberg D, Bharati IS, Nomura N, Chao Y, Pastorino S, Pingle SC, Fogal V, Wrasidlo W, Makale M, Kesari S.

Int J Nanomedicine. 2013;8:3991-4006. doi: 10.2147/IJN.S51949. Epub 2013 Oct 21.

15.

IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.

Gomez-Cabrero A, Wrasidlo W, Reisfeld RA.

PLoS One. 2013 Aug 27;8(8):e73607. doi: 10.1371/journal.pone.0073607. eCollection 2013.

16.

Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Ibsen S, Su Y, Norton J, Zahavy E, Hayashi T, Adams S, Wrasidlo W, Esener S.

J Mass Spectrom. 2013 Jul;48(7):768-73. doi: 10.1002/jms.3221.

17.

Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.

Ibsen S, Zahavy E, Wrasidlo W, Hayashi T, Norton J, Su Y, Adams S, Esener S.

Photochem Photobiol. 2013 May-Jun;89(3):698-708. doi: 10.1111/php.12045. Epub 2013 Mar 6.

18.

Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains.

Chao Y, Makale M, Karmali PP, Sharikov Y, Tsigelny I, Merkulov S, Kesari S, Wrasidlo W, Ruoslahti E, Simberg D.

Bioconjug Chem. 2012 May 16;23(5):1003-9. doi: 10.1021/bc200685a. Epub 2012 Apr 26.

19.

Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.

Tsigelny IF, Sharikov Y, Wrasidlo W, Gonzalez T, Desplats PA, Crews L, Spencer B, Masliah E.

FEBS J. 2012 Mar;279(6):1000-13. doi: 10.1111/j.1742-4658.2012.08489.x. Epub 2012 Feb 27.

20.

Assembly and targeting of liposomal nanoparticles encapsulating quantum dots.

Mukthavaram R, Wrasidlo W, Hall D, Kesari S, Makale M.

Bioconjug Chem. 2011 Aug 17;22(8):1638-44. doi: 10.1021/bc200201e. Epub 2011 Aug 1.

21.

Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model.

Liao D, Liu Z, Wrasidlo WJ, Luo Y, Nguyen G, Chen T, Xiang R, Reisfeld RA.

Cancer Res. 2011 Sep 1;71(17):5688-96. doi: 10.1158/0008-5472.CAN-11-1264. Epub 2011 Jul 22.

22.

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA.

Cancer Cell. 2011 Jun 14;19(6):715-27. doi: 10.1016/j.ccr.2011.04.016.

23.

Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity.

Liao D, Liu Z, Wrasidlo W, Chen T, Luo Y, Xiang R, Reisfeld RA.

Nanomedicine. 2011 Dec;7(6):665-73. doi: 10.1016/j.nano.2011.03.001. Epub 2011 Mar 17.

PMID:
21419870
24.

Synthesis of 5-(6-hydroxy-7H-purine-8-ylthio)- 2-(N-hydroxyformamido)pentanoic acid.

Zhang Y, Elliot G, Saldanha A, Tsigelny I, Carson D, Wrasidlo W.

Beilstein J Org Chem. 2010 Sep 1;6:742-7. doi: 10.3762/bjoc.6.93.

25.

Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model.

Erten A, Wrasidlo W, Scadeng M, Esener S, Hoffman RM, Bouvet M, Makale M.

Nanomedicine. 2010 Dec;6(6):797-807. doi: 10.1016/j.nano.2010.06.005. Epub 2010 Jul 3.

26.

Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.

Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh DA.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304. doi: 10.1073/pnas.0909299107. Epub 2010 Feb 12.

27.

Eradication of CD19+ leukemia by targeted calicheamicin θ.

Bernt KM, Prokop A, Huebener N, Gaedicke G, Wrasidlo W, Lode HN.

Bioconjug Chem. 2009 Aug 19;20(8):1587-94. doi: 10.1021/bc900128h. Epub 2009 Jul 2.

PMID:
19572629
28.

Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.

Chan M, Hayashi T, Kuy CS, Gray CS, Wu CC, Corr M, Wrasidlo W, Cottam HB, Carson DA.

Bioconjug Chem. 2009 Jun;20(6):1194-200. doi: 10.1021/bc900054q.

29.

Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.

Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB.

Clin Cancer Res. 2009 Jan 15;15(2):553-60. doi: 10.1158/1078-0432.CCR-08-2081.

30.

Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.

Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA.

J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. doi: 10.1124/jpet.108.144311. Epub 2008 Dec 4.

PMID:
19056934
31.

Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.

Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8. doi: 10.1073/pnas.0803728105. Epub 2008 Jul 7.

32.

The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8.

Wrasidlo W, Mielgo A, Torres VA, Barbero S, Stoletov K, Suyama TL, Klemke RL, Gerwick WH, Carson DA, Stupack DG.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2313-8. doi: 10.1073/pnas.0712198105. Epub 2008 Feb 11.

33.

Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.

Palanki MS, Dneprovskaia E, Doukas J, Fine RM, Hood J, Kang X, Lohse D, Martin M, Noronha G, Soll RM, Wrasidlo W, Yee S, Zhu H.

J Med Chem. 2007 Sep 6;50(18):4279-94. Epub 2007 Aug 9.

PMID:
17685602
34.

Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.

Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Hood J, Soll R.

Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6.

PMID:
17371238
35.

Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.

Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D.

Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. Epub 2006 Dec 15.

36.

Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.

Noronha G, Barrett K, Cao J, Dneprovskaia E, Fine R, Gong X, Gritzen C, Hood J, Kang X, Klebansky B, Li G, Liao W, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Soll R, Splittgerber U, Wrasidlo W, Zeng B, Zhao N, Zhou Y.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50. Epub 2006 Aug 22.

PMID:
16931012
37.

Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner.

Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G, Dörken B, Wieder T, Daniel PT.

Oncogene. 2003 Dec 11;22(57):9107-20.

PMID:
14647446
38.

Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.

Lange B, Schroeder U, Huebener N, Jikai J, Wenkel J, Strandsby A, Wrasidlo W, Gaedicke G, Lode HN.

Cancer Lett. 2003 Jul 18;197(1-2):225-30.

PMID:
12880986
39.

Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.

Jikai J, Shamis M, Huebener N, Schroeder U, Wrasidlo W, Wenkel J, Lange B, Gaedicke G, Shabat D, Lode HN.

Cancer Lett. 2003 Jul 18;197(1-2):219-24.

PMID:
12880985
40.

Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.

Schroeder U, Bernt KM, Lange B, Wenkel J, Jikai J, Shabat D, Amir R, Huebener N, Niethammer AG, Hagemeier C, Wiebusch L, Gaedicke G, Wrasidlo W, Reisfeld RA, Lode HN.

Blood. 2003 Jul 1;102(1):246-53. Epub 2003 Mar 6.

41.

A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models.

Wrasidlo W, Gaedicke G, Guy RK, Renaud J, Pitsinos E, Nicolaou KC, Reisfeld RA, Lode HN.

Bioconjug Chem. 2002 Sep-Oct;13(5):1093-9.

PMID:
12236791
42.

Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation.

Satchi-Fainaro R, Wrasidlo W, Lode HN, Shabat D.

Bioorg Med Chem. 2002 Sep;10(9):3023-9.

PMID:
12110325
43.

Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs.

Wrasidlo W, Schröder U, Bernt K, Hübener N, Shabat D, Gaedicke G, Lode H.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):557-60.

PMID:
11844671
44.

Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility.

Niethammer A, Gaedicke G, Lode HN, Wrasidlo W.

Bioconjug Chem. 2001 May-Jun;12(3):414-20.

PMID:
11353540
45.

Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.

Knoll K, Wrasidlo W, Scherberich JE, Gaedicke G, Fischer P.

Cancer Res. 2000 Nov 1;60(21):6089-94.

46.

Monoclonal antibody 138H11 against gamma-glutamyltransferase provides a possible tool for targeting calicheamicin theta to renal cell carcinomas.

Schmidt CS, Wrasidlo W, Kaufmann O, Scherberich JE, Gaedicke G, Fischer P.

Adv Exp Med Biol. 1998;451:431-6. No abstract available.

PMID:
10026907
47.
48.

In vivo efficacy of novel synthetic enediynes 1.

Wrasidlo W, Hiatt A, Mauch S, Merlock RA, Nicolaou KC.

Acta Oncol. 1995;34(2):157-64.

PMID:
7718252
49.

Conformation of a water-soluble derivative of taxol in water by 2D-NMR spectroscopy.

Gomez Paloma L, Guy RK, Wrasidlo W, Nicolaou KC.

Chem Biol. 1994 Oct;1(2):107-12.

PMID:
9383378
50.

Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis.

Nicolaou KC, Pitsinos EN, Theodorakis EA, Saimoto H, Wrasidlo W.

Chem Biol. 1994 Sep;1(1):57-66.

PMID:
9383371

Supplemental Content

Loading ...
Support Center